Business Context and Reporting Period
This Form 8-K is a current report filed by MEI Pharma, Inc. (trading symbol: MEIP) on April 10, 2020. The filing addresses corporate governance changes, specifically the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel appointments and does not contain financial performance data.
Material Changes
The primary material change reported is the expansion of the Board of Directors by one seat and the appointment of Ms. Cheryl Cohen as a new director effective April 10, 2020. Her term expires at the fiscal year 2023 annual meeting of stockholders.
Guidance, Outlook, and Management Commentary
There is no financial guidance, outlook, or management commentary regarding business operations in this filing. The document details Ms. Cohen's extensive background in the pharmaceutical and biotechnology sectors, including roles at Medivation, Johnson & Johnson, and various board memberships. Regarding compensation, Ms. Cohen received an initial stock option grant to purchase 30,000 shares of common stock at the closing price on April 9, 2020. This includes 20,000 shares vesting over three years and 10,000 shares vesting monthly over twelve months.
Important Facts for Investors to Verify
- Confirmation of the Board size increase and the specific term expiration date for the new director.
- Details of the stock option grant, including the exercise price based on the April 9, 2020 closing price and the vesting schedules.
- Verification that no related party transactions or material contracts exist involving the new director.
- Review of the press release dated April 14, 2020, attached as Exhibit 99.1 for additional context.